- Home
- GRX vs PLX Comparison
GRX vs PLX Comparison
Compare GRX & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRX
- PLX
- Stock Information
- Founded
- GRX 2007
- PLX 1993
- Country
- GRX United States
- PLX United States
- Employees
- GRX N/A
- PLX N/A
- Industry
- GRX Finance/Investors Services
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GRX Finance
- PLX Health Care
- Exchange
- GRX Nasdaq
- PLX Nasdaq
- Market Cap
- GRX 154.8M
- PLX 160.2M
- IPO Year
- GRX N/A
- PLX 1998
- Fundamental
- Price
- GRX $9.56
- PLX $1.55
- Analyst Decision
- GRX
- PLX Strong Buy
- Analyst Count
- GRX 0
- PLX 1
- Target Price
- GRX N/A
- PLX $15.00
- AVG Volume (30 Days)
- GRX 39.7K
- PLX 1.4M
- Earning Date
- GRX 01-01-0001
- PLX 05-09-2025
- Dividend Yield
- GRX 5.98%
- PLX N/A
- EPS Growth
- GRX N/A
- PLX N/A
- EPS
- GRX 0.26
- PLX 0.05
- Revenue
- GRX N/A
- PLX $59,764,000.00
- Revenue This Year
- GRX N/A
- PLX $65.02
- Revenue Next Year
- GRX N/A
- PLX $57.34
- P/E Ratio
- GRX $38.50
- PLX $32.18
- Revenue Growth
- GRX N/A
- PLX 0.18
- 52 Week Low
- GRX $7.73
- PLX $0.82
- 52 Week High
- GRX $10.40
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- GRX 51.27
- PLX 30.03
- Support Level
- GRX $9.43
- PLX $1.54
- Resistance Level
- GRX $9.56
- PLX $1.79
- Average True Range (ATR)
- GRX 0.12
- PLX 0.11
- MACD
- GRX 0.02
- PLX -0.02
- Stochastic Oscillator
- GRX 86.96
- PLX 27.27
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.